Endothelial cells (EC) lining the blood vessels regulate the stiffness of the vessel, act as filtration barriers, and maintain the cardiovascular system. Glycocalyx coating, a porous structure that is continuously synthesized and shed, is essential for EC functioning. At inflamed vascular sites, shedding exceeds synthesis leading to increased permeability and reduced thickness of glycocalyx causing dysfunctional cell signal transmission. GlycoFix aims to reverse this condition.


Technology Overview

Researchers at Northeastern University have focused on the restoring of the glycocalyx layer (made up of glycosaminoglycans, most commonly heparan sulfate) and the vasculoprotective EC signaling in the inflamed conditions. GlycoFix is a blend of heparan sulfate (extracted exogenously from Porcine mucosal tissue) and sphingosine-1-phosphate. Heparan sulfate replenishes the shedding component of the glycocalyx layer, and sphingosine phosphate aids in cell growth, mitigation, and reducing the porosity of the glycocalyx layer. This shows promising results for delaying the onset of diseases such as atherosclerosis.



  • GlycoFix can restore:
    • Lost heparan sulfate from glycocalyx layer
    • Porosity of the layer
    • Intercellular communication of vascular cells
  •  Minimal adverse response as the components are biologically derived 



  • GlycoFix can help to prevent or delay the onset of atherosclerosis and related disease conditions. Specific uses include:
    • Intravenous route to prevent glycocalyx loss during the administration of blood/fluids
    • Stent coating to prevent endothelial glycocalyx damage during deploy
    • Oral route in the case of severe inflammation due to a disease or after a surgery



  • License
  • Research collaboration
  • Partnering
Patent Information:
For Information, Contact:
Colin Sullivan
Commercialization Consultant
Northeastern University
Eno Ebong
Solomon Mensah
Ming Cheng
Ronodeep Mitra